Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for catalyzing to synthesize Atazanir intermediate and application thereof

A technology of atazanavir and intermediates, which is applied in the field of catalytic synthesis of atazanavir intermediates, can solve the problems of low reaction efficiency, unreusable carbonyl reductase, and high requirements for reaction conditions, and achieves high cumulative product concentration and convenient Separation and purification, the effect of reducing energy consumption

Inactive Publication Date: 2019-08-02
SHANGHAI UNIV OF MEDICINE & HEALTH SCI
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, in the existing methods for the biosynthesis of atazanavir intermediates, there are problems such as high requirements for reaction conditions, non-recyclable carbonyl reductase, and low reaction efficiency.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for catalyzing to synthesize Atazanir intermediate and application thereof
  • Method for catalyzing to synthesize Atazanir intermediate and application thereof
  • Method for catalyzing to synthesize Atazanir intermediate and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] This example discloses a method for catalytically synthesizing an atazanavir intermediate, using (S)-tert-butyl (4-chloro-3-carbonyl-1-phenylbutyl-2-yl) carbamate as Substrate, with carbonyl reductase NaSDR and coenzyme as catalyst, catalyzed synthesis of tert-butyl ((2S,3R)-4-chloro-3-hydroxyl-1-benzene in the system where co-substrate, cosolvent and buffer exist Butyl-2-yl) carbamate; the carbonyl reductase is immobilized on the resin.

[0037] Specifically include the following steps:

[0038] S1: immobilizing carbonyl reductase on the resin;

[0039] S2: Substrate (S)-tert-butyl (4-chloro-3-carbonyl-1-phenylbutyl-2-yl) carbamate, co-substrate, co-immobilized enzyme system, co-solvent and buffer solution into the reactor, the reaction pH value is 8.0-11.0, and the reaction temperature is 25-30°C. After 3-6 hours of reaction, tert-butyl ((2S,3R)-4-chloro-3-hydroxy-1 -phenylbutyl-2-yl)carbamate.

[0040] Step S1 includes:

[0041] S11: Soak the resin in TEA buffer...

Embodiment 2

[0049] This embodiment discloses a method for preparing a crude enzyme solution of carbonyl reductase NaSDR, which specifically includes the following steps:

[0050] 1. Activation of E.coli-NaSDR bacteria

[0051] On the LB solid plate containing kanamycin (50μg / ml), the bacterial solution was coated by the method of partitioning or dilution. After culturing at 37°C for 20 hours, a single colony of activated E.coli-NaSDR was obtained.

[0052] 2. Fermentation and cultivation of E.coli-NaSDR bacteria

[0053] (1) Inoculate a single colony of E.coli-NaSDR bacteria into 5ml primary seed medium, and cultivate it at 37°C and 220rpm for 11 hours, and the OD600 reaches 0.9-1.2, which is the primary seed solution.

[0054](2) Inoculate 5 ml of the primary seed solution into the fermentation medium (2.5% inoculum size), and cultivate at 37° C. and 220 rpm for 2-3 hours. When the OD600 of the fermentation medium reaches 0.9-1.2, add 400 μL of IPTG (isopropylthiogalactopyranoside, co...

Embodiment 3

[0058] This embodiment discloses a resin pretreatment method, the specific steps are as follows:

[0059] Soak 1 g of resin in pH 10.5 TEA buffer for 1 hour, remove supernatant and floating impurities, add 500ul of 25% glutaraldehyde to the resin, add TEA buffer to a final volume of 10ml, make the volume of glutaraldehyde The score is 1.25%. Under the condition of 30°C, place it on a shaker at 230 rpm for 4 hours, then filter with filter paper to obtain the activated resin, rinse the activated resin three times with TEA buffer to remove glutaraldehyde, and drain it for later use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of medicines, and particularly relates to a method for catalyzing to synthesize an Atazanir intermediate and application thereof. The method for catalyzing to synthesize the Atazanir intermediate comprises the following steps of using (S)-tertiary butyl(4-chloro-3-carbonyl-1-phenylbutyl-2-yl)carbamate as a substrate, using carbonyl reductase NaSDR and auxiliary enzyme as catalysts, and catalyzing to synthesize tertiary butyl((2S,3R)-4-chloro-3-hydroxy-1-phenylbutyl-2-yl)carbamate in a system containing a cosubstrate, a cosolvent and a buffer solution; immobilizing the carbonyl reductase onto resin. Compared with a disclosed enzyme catalyzing preparation method, the method has the advantages that the reaction temperature is milder, and the reaction systemis simpler; the immobilized carbonyl reductase has the advantages of repeatability, high accumulation concentration of product and the like, the energy consumption is decreased, the cost is saved, andthe accumulation concentration of the product is greatly increased by the repeated utilization.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a method for catalytically synthesizing an atazanavir intermediate and an application thereof. Background technique [0002] Atazanavir sulfate (CAS: 198904-31-3) is currently the main anti-AIDS drug in the world. It was developed by Bristol-Myers Squibb in the United States. It was first listed in the United States in June 2003. It is mainly combined with other antiretroviral A combination of drugs to treat HIV infection. Because it is only taken once a day, it has the advantages of rapid absorption and fewer adverse reactions than other anti-HIV virus infection drugs, and compared with other protease inhibitors, atazanavir does not interfere with normal diet during medication. After the FDA approved the listing in 2003, the global sales of the drug in 2009 were 5.2 billion US dollars, ranking 70th. With the frequent outbreaks of virus epidemics worldwide and the deepening of AIDS prev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12P13/00C07C271/16C07D213/42
CPCC07C271/16C07D213/42C12P13/00
Inventor 邵雷吴锴杨志钧
Owner SHANGHAI UNIV OF MEDICINE & HEALTH SCI